Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PCRX 01.02.2025
Drug:bupivacaine-liposome EXPAREL®
Drug:triamcinolone-acetonide ZILRETTA®
Drug:cold-therapy-device ioverao®
Drug:gene-therapy PCRX-201
Diseases:postsurgical pain management
Diseases:osteoarthritis knee pain
Diseases:pain control
Diseases:osteoarthritis
Date of Upcoming Event:2025-01-15
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
About Gravity Analytica
PARSIPPANY, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) --Pacira BioSciences, Inc.(NASDAQ: PCRX) today announced that it will present at the 43rdAnnual J.P. Morgan Healthcare Conference at 10:30 AM PT (1:30 PM EST) on Wednesday, January 15, 2025. Live audio of the event can be accessed by visiting the “Events” page of the company’s website atinvestor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
About PaciraPacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioverao®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visitwww.pacira.com.
Company Contact:Pacira BioSciences, Inc.Christian Pedetti(973) 254-4387Christian.pedetti@pacira.com